

# ESTRUCT COURT OF CUEVELAND COUNTY PART C

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,

Plaintiff,

٧.

- (1) PURDUE PHARMA L.P.;
- (2) PURDUE PHARMA, INC.;
- (3) THE PURDUE FREDERICK COMPANY:
- (4) TEVA PHARMACEUTICALS USA, INC.;
- (5) CEPHALON, INC.;
- (6) JOHNSON & JOHNSON;
- (7) JANSSEN PHARMACEUTICALS, INC.;
- (8) ORTHO-McNEIL-JANSSEN
  PHARMACEUTICALS, INC., n/k/a
  JANSSEN PHARMACEUTICALS, INC.;
- (9) JANSSEN PHARMACEUTICA, INC., n/k/a JANSSEN PHARMACEUTICALS, INC.;
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON PHARMACEUTICALS, INC.;
- (11) WATSON LABORATORIES, INC.:
- (12) ACTAVIS LLC; and
- (13) ACTAVIS PHARMA, INC., f/k/a WATSON PHARMA, INC.,


Defendants.

STATE OF OKLAHOMA S.S. CLEVELAND COUNTY S.S. FILED In The Office of the Court Clerk

In the office of the Court Clerk MARILYN WILLIAMS

Case No. CJ-2017-816 Honorable Thad Balkman

William C. Hetherington Special Discovery Master



DEFENDANTS TEVA PHARMACEUTICALS USA, INC., CEPHALON, INC., WATSON LABORATORIES, INC., ACTAVIS LLC, AND ACTAVIS PHARMA, INC., f/k/a WATSON PHARMA, INC.'S RESPONSE IN OPPOSITION TO PLAINTIFF'S MOTION TO COMPEL DEPOSITIONS

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,	) }
· · · · · · · · · · · · · · · · · · ·	ý.
Plaintiff,	)
vs.	Case No. CJ-2017-816 Judge Thad Balkman
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
Defendants	)

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
November 19, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails:

(405) 516-7859

mburrage@whittenburragelaw.com rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL

313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone:

(405) 521-3921

Facsimile:

(405) 521-6246

**Emails:** 

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum
Mark S. Cheffo
Hayden A. Coleman
Paul LaFata
Dechert LLP
Three Bryant Park
New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. See 12 O.S. §3230(C)(5).

1. Your efforts to identify high-prescribing health care providers in the State of Oklahoma.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
(4) DETERMINED DELA DALLA Y VI	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Dofondanto	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teya/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
November 20, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

## jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone:

(405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Your efforts to identify low-prescribing health care providers in the State of Oklahoma.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,	) )
Plaintiff,	, ) )
vs.	Case No. CJ-2017-816  Judge Thad Balkman
(1) PURDUE PHARMA L.P.; (2) PURDUE PHARMA, INC.; (3) THE PURDUE FREDERICK COMPANY; (4) TEVA PHARMACEUTICALS USA, INC.; (5) CEPHALON, INC.; (6) JOHNSON & JOHNSON; (7) JANSSEN PHARMACEUTICALS, INC; (8) ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS; (9) JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS, INC.; (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON PHARMACEUTICALS, INC.; (11) WATSON LABORATORIES, INC.; (12) ACTAVIS LLC; and (13) ACTAVIS PHARMA, INC.,	Special Master:  William Hetherington
f/k/a WATSON PHARMA, INC.,	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

### TO:

### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
November 26, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: (405) 516-7800 Faccimile: (405) 516-7850

Facsimile: (405) 516-7859 Emails: mburrage@whi

mburrage@whittenburragelaw.com rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone: (405) 521-3921

Telephone: (405) 521-3921 Facsimile: (405) 521-6246

Facsimile: (40 Emails: mil

mike.hunter@oag.ok.gov

abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

## jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Amounts spent by You on advertising and marketing related to opioids.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
DI. * .4*66	)
Plaintiff,	)
•	) Case No. CJ-2017-816
VS.	Judge Thad Balkman
(1) BUDDITE DITADMA I D.	) Special Masters
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

## TO:

### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
November 27, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: (405) 516-7800

Facsimile: (405) 516-7859

Emails: mburrage@whittenburragelaw.com rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone: (405) 521-3921

Telephone: (405) 521-3921 Facsimile: (405) 521-6246

Emails: mike.hunter@oag.ok.gov

abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone: (405) 516-7800 Facsimile: (405) 516-7859

Emails: bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Amounts spent by You on research and development for opioids.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	) ·
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
·	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants.	)

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

## VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

## COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
November 28, 2018	9:00 a.m.	511 Couch Drive Suite 100
		Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails: (405) 516-7859 mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

## jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

 Your educational and/or research grants provided by You to individuals or entities regarding opioids and/or pain treatment.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
VS.	) Judge Thad Balkman
4	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	.)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants.	)

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 21, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails:

(405) 516-7859 mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 **GENERAL COUNSEL TO** THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 **DEPUTY GENERAL COUNSEL** 313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone:

Facsimile:

(405) 521-3921

Emails:

(405) 521-6246 mike.hunter@oag.ok.gov

abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone:

(405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

> /s/ Michael Burrage Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

 Your actions and/or efforts in response to the FDA's September 10, 2013 response to the PROP Petition from July 25, 2012.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	
Digintiff	)
Plaintiff,	)
vs.	) Case No. CJ-2017-816 ) Judge Thad Balkman
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

## VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 24, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails: (405) 516-7859

mburrage@whittenburragelaw.com rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503

ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL

313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone: (405) 521-39

Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 (405) 601-1616 gcoffee@glenncoffee.com Telephone:

Email:

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

# Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. See 12 O.S. §3230(C)(5).

 Your role, influence, or support for any campaign or movement to declare pain as the "Fifth Vital Sign."

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
Plaintiff,	)
1 1411111111111111111111111111111111111	Case No. CJ-2017-816
TIE	) Judge Thad Balkman
VS.	) Judge Had Daikman
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	) )
(4) TEVA PHARMACEUTICALS USA, INC.;	ĺ
(5) CEPHALON, INC.;	j ·
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

#### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 25, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300 Oklahoma City, OK 73102

Telephone: (4

(405) 516-7800

Facsimile:

(405) 516-7859

Emails: mb

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

0111 07 07

Oklahoma City, OK 73105 Telephone: (405) 521-39

Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov

abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Your interactions and communications with medical schools in Oklahoma, including without limitation, financial contributions, speeches, presentations, scholarships, event sponsorship, research grants, educational materials, and/or branded promotional materials.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
(A) DIVIDAGE DE L'ANDRE DE L'ANDR	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Dofondonto	`

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

#### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 26, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

<u>/s/ Michael Burrage</u>

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: Facsimile:

(405) 516-7800 (405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 (405) 601-1616 Telephone:

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

 Your use of public relations firms and communication with journalists regarding opioids and/or pain management marketing, including without limitation, the American Enterprise Institute, Cancer Action Network, Center for Lawful Access & Abuse Deterrence, Pinney Associates, Conrad & Associates LLC, and Sense About Science USA.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
	<u>)</u> .
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	<u>)</u>
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	) .
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Dofondante	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

## VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 27, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800 (405) 516-7859

Facsimile: Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone: (405) 521-3

Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## CERTIFICATE OF SERVICE

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

### Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

The amount of revenue and profits earned by You attributable to and/or derived from the
prescription of opioids by any Oklahoma doctor criminally investigated, charged, indicted,
and/or prosecuted for prescribing practices related to opioids. For purposes of this topic,
"prosecution" includes any administrative proceeding.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
DI-2-4266	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	Judge Thad Balkman
	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
September 28, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: (40 Facsimile: (40

(405) 516-7800 (405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102

Telephone:

(405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

 Your use of medical education communication companies (MECCs) regarding opioids and/or pain management marketing.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	<b>)</b>
Plaintiff,	) Case No. CJ-2017-816
VS.	) Judge Thad Balkman
(1) PURDUE PHARMA L.P.;	) Special Master: ) William Hetherington
(2) PURDUE PHARMA, INC.; (3) THE PURDUE FREDERICK COMPANY;	) william Hether ington
(4) TEVA PHARMACEUTICALS USA, INC.; (5) CEPHALON, INC.;	
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC; (8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	j ·
JANSSEN PHARMACEUTICALS; (9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	ý
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	
(11) WATSON LABORATORIES, INC.; (12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC., f/k/a WATSON PHARMA, INC.,	) .
iwa waison i nama, ne,	)
Defendante	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
October 1, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: Facsimile:

(405) 516-7800 (405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL

313 N.E. 21st Street Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

### **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Your use of speakers' bureaus, advisory boards, or other similar programs regarding opioids and/or pain management marketing.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
	)
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	· .
,	)
Defendants	í ·

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
October 2, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails: (405) 516-7859 mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105 Telephone: (405) 521-39

Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

## jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Your use of medical liaisons to communicate with Healthcare Professionals, KOLs, and/or Front Groups regarding opioids and/or pain treatment.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	
·	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
	) william Hetherington
(3) THE PURDUE FREDERICK COMPANY;	· ·
(4) TEVA PHARMACEUTICALS USA, INC.;	<b>?</b>
(5) CEPHALON, INC.;	?
(6) JOHNSON & JOHNSON;	<b>)</b>
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	)
JANSSEN PHARMACEUTICALS;	)
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	
(11) WATSON LABORATORIES, INC.;	
(12) ACTAVIS LLC; and	
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	j
Defendants	\(\cdot\)

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

## VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
October 3, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: (40

(405) 516-7800

Facsimile: Emails: (405) 516-7859 mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone: Facsimile:

(405) 521-3921 (405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

## jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

 Your use of data provided by IMS, IQVIA or any similar data service for purposes of marketing and/or sales strategies.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel.,	)
MIKE HUNTER,	
ATTORNEY GENERAL OF OKLAHOMA,	)
	)
Plaintiff,	)
	) Case No. CJ-2017-816
vs.	) Judge Thad Balkman
(1) PURDUE PHARMA L.P.;	) Special Master:
(2) PURDUE PHARMA, INC.;	) William Hetherington
(3) THE PURDUE FREDERICK COMPANY;	)
(4) TEVA PHARMACEUTICALS USA, INC.;	)
(5) CEPHALON, INC.;	)
(6) JOHNSON & JOHNSON;	)
(7) JANSSEN PHARMACEUTICALS, INC;	)
(8) ORTHO-MCNEIL-JANSSEN	)
PHARMACEUTICALS, INC., n/k/a	
JANSSEN PHARMACEUTICALS;	
(9) JANSSEN PHARMACEUTICA, INC.,	)
n/k/a JANSSEN PHARMACEUTICALS, INC.;	)
(10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,	)
f/k/a ACTAVIS, INC., f/k/a WATSON	)
PHARMACEUTICALS, INC.;	)
(11) WATSON LABORATORIES, INC.;	)
(12) ACTAVIS LLC; and	)
(13) ACTAVIS PHARMA, INC.,	)
f/k/a WATSON PHARMA, INC.,	)
	)
Defendants	1

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

#### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

#### COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
October 4, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone: Facsimile:

(405) 516-7800 (405) 516-7859

Emails:

mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone:

(405) 521-3921

Facsimile:

(405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone: (405) 601-1616

Email:

gcoffee@glenncoffee.com

# ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Your use of clinical trial companies regarding opioids and/or pain management.

# IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER,	)
ATTORNEY GENERAL OF OKLAHOMA,	<b>,</b>
Plaintiff,	) (ase No. CJ-2017-816)
vs.	) Judge Thad Balkman
(1) PURDUE PHARMA L.P.; (2) PURDUE PHARMA, INC.; (3) THE PURDUE FREDERICK COMPANY; (4) TEVA PHARMACEUTICALS USA, INC.; (5) CEPHALON, INC.; (6) JOHNSON & JOHNSON; (7) JANSSEN PHARMACEUTICALS, INC; (8) ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS; (9) JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS, INC.; (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON PHARMACEUTICALS, INC.; (11) WATSON LABORATORIES, INC.; (12) ACTAVIS LLC; and	Special Master: William Hetherington
(13) ACTAVIS PHARMA, INC.,	,
f/k/a WATSON PHARMA, INC.,	
Defendante	

AMENDED NOTICE FOR 3230(C)(5) VIDEOTAPED DEPOSITION OF CORPORATE REPRESENTATIVE(S) OF TEVA/CEPHAPLON DEFENDANTS

#### TO:

#### VIA email

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

### VIA email

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

## COUNSEL FOR THE TEVA/CEPHALON DEFENDANTS

Please take notice that, on the date and at the time indicated below, Plaintiff will take the deposition(s) upon oral examination of the corporate representative(s) of Defendants, TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. (collectively, the "Teva/Cephalon Defendants") in accordance with 12 O.S. §3230(C)(5). The Teva/Cephalon Defendants shall designate one or more officers, directors, managing agents, or other persons who consent to testify on the Teva/Cephalon Defendants' behalf regarding the subject matters identified in Appendix A.

The oral and video deposition(s) will occur as follows:

DATE	TIME	LOCATION
October 5, 2018	9:00 a.m.	511 Couch Drive Suite 100 Oklahoma City, Oklahoma 73102

Said depositions are to be used as evidence in the trial of the above cause, the same to be taken before a qualified reporter and shall be recorded by videotape. Said depositions when so taken and returned according to law may be used as evidence in the trial of this cause and the taking of the same will be adjourned and continue from day-to-day until completed, at the same place until it is completed.

PLEASE TAKE FURTHER NOTICE that each such officer, agent or other person produced by the Teva/Cephalon Defendants to so testify under 12 O.S. §3230(C)(5) has an affirmative duty to have first reviewed all documents, reports, and other matters known or reasonably available to the Teva/Cephalon Defendants, along with all potential witnesses known or reasonable available to the Teva/Cephalon Defendant in order to provide informed binding answers at the deposition(s).

Dated: August 8, 2018

/s/ Michael Burrage

Michael Burrage, OBA No. 1350 Reggie Whitten, OBA No. 9576 WHITTEN BURRAGE 512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile: Emails: (405) 516-7859 mburrage@whittenburragelaw.com

rwhitten@whittenburragelaw.com

Mike Hunter, OBA No. 4503 ATTORNEY GENERAL FOR THE STATE OF OKLAHOMA Abby Dillsaver, OBA No. 20675 GENERAL COUNSEL TO THE ATTORNEY GENERAL Ethan A. Shaner, OBA No. 30916 DEPUTY GENERAL COUNSEL 313 N.E. 21st Street

Oklahoma City, OK 73105

Telephone:

(405) 521-3921

Facsimile:

(405) 521-6246

Emails:

mike.hunter@oag.ok.gov abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Bradley E. Beckworth, OBA No. 19982 Jeffrey J. Angelovich, OBA No. 19981 NIX, PATTERSON & ROACH, LLP 512 N. Broadway Avenue, Suite 200 Oklahoma City, OK 73102

Telephone:

(405) 516-7800

Facsimile:

(405) 516-7859

Emails:

bbeckworth@nixlaw.com

# jangelovich@npraustin.com

Glenn Coffee, OBA No. 14563 GLENN COFFEE & ASSOCIATES, PLLC 915 N. Robinson Ave. Oklahoma City, OK 73102 Telephone:

(405) 601-1616

Email:

gcoffee@glenncoffee.com

## ATTORNEYS FOR PLAINTIFF

## **CERTIFICATE OF SERVICE**

I certify that a true and correct copy of the above and foregoing was emailed on August 8, 2018 to:

Sanford C. Coats, OBA No. 18268 Cullen D. Sweeney, OBA No. 30269 CROWE & DUNLEVY, P.C. Braniff Building 324 N. Robinson Ave., Ste. 100 Oklahoma City, OK 73102

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul LaFata Dechert LLP Three Bryant Park New York, New York 10036

Patrick J. Fitzgerald R. Ryan Stoll SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 155 North Wacker Drive, Suite 2700 Chicago, Illinois 60606

Robert G. McCampbell, OBA No. 10390 Travis J. Jett, OBA No. 30601 GABLEGOTWALS One Leadership Square, 15th Floor 211 North Robinson Oklahoma City, OK 73102-7255

Steven A. Reed Harvey Bartle IV Jeremy A. Menkowitz MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921

Brian M. Ercole MORGAN, LEWIS & BOCKIUS LLP 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131 Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072

Charles C. Lifland Jennifer D. Cardelus O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071

Stephen D. Brody O'MELVENY & MYERS LLP 1625 Eye Street NW Washington, DC 20006

/s/ Michael Burrage
Michael Burrage

## Appendix A

The matters on which examination is requested are itemized below. The Teva/Cephalon Defendants must designate persons to testify as to each subject of testimony. This designation must be delivered to Plaintiff prior to or at the commencement of the taking of the deposition. *See* 12 O.S. §3230(C)(5).

1. Clinical trials funded, sponsored, and/or conducted by You regarding opioids and/or pain management.